Personal profile
Headline
Mount Sinai Professor in Cancer Biology
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Oncological Sciences
PROFESSOR | Immunology & Immunotherapy
Biography
Samir Parekh, MD, is Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. He is Director of the Center of Excellence for Multiple Myeloma and Section Head of Multiple Myeloma in the Division of Hematology and Medical Oncology. Dr. Parekh is Co-Leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute at Icahn Mount Sinai and a faculty member of the Icahn Genomics Institute and Marc and Jennifer Lipschultz Precision Immunology Institute.
Dr. Parekh's research focuses on the pathogenesis of hematological malignancies and development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly multiple myeloma and Non-Hodgkin's lymphoma.
Dr. Parekh currently serves on grant review committees for the National Institutes of Health, Department of Defense and Multiple Myeloma Research Foundation; he is a member of the American Society of Hematology Plasma cell committee and the American Society of Clinical Investigation. Dr. Parekh has led innovative investigator-initiated precision medicine trials testing novel small molecules and NGS-guided drug repurposing using RNA-and DNA-sequencing to salvage end-stage myeloma patients. His lab has served as an international reference unit for studying the immune effects of novel cereblon modulators (Celmods) Iberdomide and Mezigdomide. His observations on the side effects of CART and bispecific therapy have led to increased safety, better patient selection and awareness of infectious complications of these powerful novel therapeutics.
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma
Pan, D., Mouhieddine, T. H., Sheng, T., Fu, W., Moshier, E., Richter, J., Parekh, S., Jagannath, S., Chari, A., Rossi, A. C., Sanchez, L. J., Thibaud, S., Rodriguez, C., Cho, H. J. & Richard, S., May 2026, In: Bone Marrow Transplantation. 61, 5, p. 639-641 3 p.Research output: Contribution to journal › Letter › peer-review
-
Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8
Chen, H., Dutta, R. P., Li, Z., Zhong, Y., Ma, A., Park, K. S., Kottur, J., Park, A., Babault, N., Wang, K., Wang, D., Xiong, Y., Kaniskan, H. Ü., Luo, M., Parekh, S. & Jin, J., 26 Feb 2026, In: Journal of Medicinal Chemistry. 69, 4, p. 4255-4269 15 p.Research output: Contribution to journal › Article › peer-review
Open Access -
EARLIER USE OF CILTACABTAGENE AUTOLEUCEL IS ASSOCIATED WITH BETTER IMMUNE FITNESS AND STRONGER IMMUNE EFFECTS AS SHOWN BY CORRELATIVE ANALYSIS OF PERIPHERAL BLOOD AND THE BONE MARROW TUMOR MICROENVIRONMENT FROM THE CARTITUDE-4 STUDY
Van De Donk, N. W. C. J., Parekh, S., Li, K., Lin, Y., Martin, T. G., Han, S., De Oca, R. M., Suraneni, M., Gormley, M., Hodkinson, B., Yuan, J., Wang, F., Kumar, A., Yin, D., Smirnov, D., Patel, J., Lendvai, N., Madduri, D., Zhu, J. & Koneru, M. & 4 others, , Jan 2026, In: Haematologica. 111, 92.Research output: Contribution to journal › Article › peer-review
Open Access -
Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility
del Rosal, M. V., He, M. Z., Jagannath, S., Parekh, S., Kloog, I., Arora, M. & Thibaud, S., 2026, (Accepted/In press) In: Blood Reviews. 101392.Research output: Contribution to journal › Review article › peer-review
Open Access -
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression
Vieira dos Santos, J., Melnekoff, D. T., Aleman, A., Mouhieddine, T. H., Montes de Oca, R., Wang, F., Rajeeve, S., Bhalla, S., Van Oekelen, O., Upadhyaya, B., Ghodke-Puranik, Y., Leshchenko, V., Kim-Schulze, S., Rahman, A., Afik, S., Lewinsky, H., Plaks, V., Thibaud, S., Cho, H. J. & Richter, J. & 9 others, , 10 Feb 2026, In: Blood advances. 10, 3, p. 604-607 4 p.Research output: Contribution to journal › Article › peer-review
Open Access
Press/Media
-
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
22/05/26
1 item of Media coverage
Press/Media
-
Reversing T Cell Exhaustion Improves Effectiveness of Myeloma Immunotherapies
18/05/26 → 19/05/26
6 items of Media coverage
Press/Media
-
Overcoming T Cell Exhaustion Enhances the Success of Myeloma Immunotherapies
18/05/26
2 items of Media coverage
Press/Media
-
Recent Findings from Icahn School of Medicine at Mount Sinai Advance Knowledge in Multiple Myeloma (Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab)
Moshier, E., Sastow , D., Richter, J., Lancman, G., Parekh, S., Jagannath, S., Chari, A., Cho, H. & Rodriguez, C.
30/04/26
1 item of Media coverage
Press/Media
-
Studies from Icahn School of Medicine at Mount Sinai in the Area of Multiple Myeloma Reported (Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8)
Zhong, Y., Parekh, S., Kaniskan, Ü., Jin, J. & Dutta, R. P.
27/02/26
1 item of Media coverage
Press/Media